Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRM-001 is a polynucleotide (PN) based injectable skin enhancer developed by PharmaResearch Co., Ltd. for aesthetic and regenerative medicine. Composed of long-chain DNA fragments derived from salmon germ cells, PRM-001 functions as a "skin booster" rather than a traditional volumizing filler. Its mechanism of action involves the activation of adenosine A2A receptors, which modulates inflammatory responses and stimulates fibroblast proliferation and collagen synthesis. Additionally, it provides a structural scaffold in the extracellular matrix and supplies nucleotides for the DNA salvage pathway, promoting endogenous tissue repair. PRM-001 is specifically being evaluated in clinical trials for the treatment of periorbital wrinkles, commonly known as crow's feet lines, to improve skin elasticity, hydration, and overall texture.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PRM-001.